Biotech Values

[DewDiligence]

Roche’s RG7716 succeeds in phase-2 DME trial:

https://www.gene.com/media/press-releases/14705/2018-02-11/phase-ii-data-support-potential-for-nove

In people with vision loss from diabetic macular edema (DME), treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab [Lucetnis] alone. Key secondary and exploratory anatomical outcomes – reduction of central retina thickness and improvements in diabetic retinopathy severity scores – were supportive of the primary outcome.

RG7716 is the first bispecific, monoclonal antibody specifically designed for the eye that simultaneously binds to and inactivates vascular endothelial growth factor A (VEGF-A) and Angiopoietin-2 (Ang-2).